Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the European Medicines Agency (EMA) has validated its Type II variation for XTANDI® (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR) who are unsuitable for salvage-radiotherapy.� Ahsan Arozullah, MD, MPH, Senior...
Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=310982
This post first appeared on Why You Should Migrate To Magento 2 Services?, please read the originial post: here
